Sugi Predict

Sugi Predict / Targets / MAOB

MAOB

Amine oxidase [flavin-containing] B · P27338 · MAOB on Sugi Atlas →

828,636 patent compounds predicted against MAOB, 440,635 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL8513 SCHEMBL8513 0.71 19/20
SCHEMBL27895 SCHEMBL27895 0.67 15/20
SCHEMBL12347 SCHEMBL12347 0.52 15/20
Methylchromone Methylchromone (SCHEMBL25934) 0.56 14/20
SCHEMBL21409 SCHEMBL21409 0.61 13/20
Linezolid Linezolid (SCHEMBL5027) 1.00 12/20
Flavanone Flavanone (SCHEMBL19745) 1.00 12/20
Selegiline Selegiline (SCHEMBL22232) 1.00 11/20
SCHEMBL22875 SCHEMBL22875 0.68 11/20
SCHEMBL22564 SCHEMBL22564 0.64 10/20
SCHEMBL22874 SCHEMBL22874 0.61 10/20
SCHEMBL23720 SCHEMBL23720 0.60 10/20
SCHEMBL21408 SCHEMBL21408 0.58 10/20
SCHEMBL15817 SCHEMBL15817 0.54 10/20
Cilostazol Cilostazol (SCHEMBL16128) 0.50 10/20
SCHEMBL23718 SCHEMBL23718 0.62 9/20
SCHEMBL23989 SCHEMBL23989 0.60 9/20
SCHEMBL13777 SCHEMBL13777 0.57 9/20
SCHEMBL13778 SCHEMBL13778 0.57 9/20
SCHEMBL23719 SCHEMBL23719 0.55 9/20

Clinical trials — most relevant to MAOB by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
MEthylene Blue In Patients With Acquired Methemoglobinemia PHASE4COMPLETED
Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD) PHASE4UNKNOWN
Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists PHASE4COMPLETED
Study of Urate Elevation in Parkinson's Disease, Phase 3 PHASE3COMPLETED
Efficacy of Isradipine in Early Parkinson Disease PHASE3COMPLETED
Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans PHASE2NOT_YET_RECRUITING
Psychedelic-assisted Group Program for First Responders PHASE1/PHASE2RECRUITING
A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome. PHASE2NOT_YET_RECRUITING
Disease-modifying Potential of Transdermal NICotine in Early Parkinson's Disease PHASE2UNKNOWN
A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease PHASE2COMPLETED
Ambroxol in Disease Modification in Parkinson Disease PHASE2COMPLETED
A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease PHASE2COMPLETED
Psilocybin for the Treatment of Veterans With Post-Traumatic Stress Disorder PHASE2ACTIVE_NOT_RECRUITING
A Clinical Study of the Performance of a Glucose Blinding Protein-Based Continuous Glucose Monitor (GBP CGM) PHASE2COMPLETED
Selegiline Patch for Treatment of Nicotine Dependence PHASE2COMPLETED
BMB-101 in Absence Epilepsy and DEE PHASE2RECRUITING
Phase II Study to Evaluate the Effectiveness of EVT 302 in Smoking Cessation. PHASE2COMPLETED
Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine Headaches PHASE2COMPLETED
Blood PREssure Augmentation in Large-vessel Occlusion Stroke Study EARLY_PHASE1SUSPENDED
A New Treatment Approach for Major Depressive Disorder Based Upon Targeting Monoamine Oxidase A (MAO-A) EARLY_PHASE1COMPLETED
TSK (Tryptophan - Serotonin - Kynurenine) Biomarkers Assessment in Stroke nanCOMPLETED
PET-MRI F-DOPA Activity in the Mesocorticolimbic System and Depressive Symptoms in the Prediction of Treatment Compatibility nanUNKNOWN
MAO-B Occupancy in Depressed Patients nanCOMPLETED
Clinical Trial of Vildagliptin in Early Parkinson's Disease nanNOT_YET_RECRUITING
An Observational Study for the Prevalence of Neuropsychiatric Symptom in Parkinson's Disease Dementia nanCOMPLETED
Pretreatment Identification of Duloxetine Success in Neuropathic Pain Patients nanCOMPLETED
Real-Time Levodopa Level Monitoring in Parkinson Disease nanRECRUITING
Selegiline and Reward Processing nanUNKNOWN
Neuroinflammation in COVID-19 and Depression nanCOMPLETED
The Effects of Dextroamphetamine on Brain Function nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a MAOB binder may also engage these)

ProteinNameSimilarity
Q5RE98 — 1.000 Q5RE98 →
Q6NSN2 — 1.000 Q6NSN2 →
P21398 — 1.000 P21398 →
Q8BW75 — 1.000 Q8BW75 →
Q6Q2J0 — 1.000 Q6Q2J0 →
Q7YRB7 — 1.000 Q7YRB7 →
Q5RE60 — 1.000 Q5RE60 →
P58028 — 1.000 P58028 →
P21396 — 1.000 P21396 →
P56560 — 1.000 P56560 →
Q64133 — 1.000 Q64133 →
Q5NU32 — 1.000 Q5NU32 →
MAOA Amine oxidase [flavin-containing] A 1.000 landscape →
P19643 — 0.999 P19643 →
P49253 — 0.999 P49253 →
P58027 — 0.997 P58027 →
Q6PLK3 — 0.995 Q6PLK3 →
Q6TGQ8 — 0.992 Q6TGQ8 →
P0CC17 — 0.990 P0CC17 →
Q0J954 — 0.988 Q0J954 →
Q4JHE2 — 0.988 Q4JHE2 →
Q8H191 — 0.986 Q8H191 →
A8QL58 — 0.986 A8QL58 →
Q90W54 — 0.985 Q90W54 →
K9N7B7 — 0.984 K9N7B7 →
P81383 — 0.984 P81383 →
O93364 — 0.984 O93364 →
B5AR80 — 0.984 B5AR80 →
P56742 — 0.984 P56742 →
Q54IT3 — 0.984 Q54IT3 →